Company research
Kailera Therapeutics, Inc.
CIK 2096997Updated Nov 6, 2026
SecurityKLRA · NASDAQ · equity
KLRA price & chart
Loading TradingView…
NASDAQ:KLRA on TradingView ↗About the company
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss.
In the news
Seeking Alpha
GLP-1s: Still Early In The Growth Story ↗
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation ↗
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval ↗
SEC disclosures
Kailera Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
Offerings
Registration 333-294690
- Gross proceeds
- 625000000.0
- Net proceeds
- 581250000.0
- Deal price
- 16.0
- Shares
- 39062500
- Offering price
- $16.00
- Ticker
- KLRA
Underwriters: J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI
Registration 333-295114
Filing attachments
ck0002096997-ex99_1.htm · 8-K · 2026-11-04
Exhibit 99.1 Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates • Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA • Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data expected mid-2027 and mid-2028, respectively • Safiglipron (KAI-7535) global Phase 2 trial fully enrolled; data now anticipated mid-2027 • KAI-4729 IND now active with U.S. FDA; …
Read attachment ↗ck0002096997-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 ck0002096997-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates • IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 • Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 • Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership • Cas…
Read attachment ↗ck0002096997-ex99_1.htm · 8-K · 2026-05-26
EX-99.1 2 ck0002096997-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates • Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline • Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program • Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, inclu…
Read attachment ↗ck0002096997-ex99_1.htm · 4 · 2026-04-20
Exhibit 99.1 BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC By: /s/ Adam Koppel Title: Partner BAIN CAPITAL LIFE SCIENCES IV GENERAL PARTNER, LLC By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Adam Koppel Title: Partner BAIN CAPITAL LIFE SCIENCES FUND IV, L.P. By: Bain Capital Life Sciences IV General Partner, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Adam Koppel Title: Partner BCLS FUND IV INVESTMENTS GP, LLC By: Bai…
Read attachment ↗d135698dex992.htm · S-8 · 2026-04-17
Exhibit 99.2 KAILERA THERAPEUTICS, INC. 2026 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILITY Service Providers are eligible to be…
Read attachment ↗ck0002096997-ex99_1.htm · 3 · 2026-04-16
Exhibit 99.1 Bain Capital Life Sciences Investors, LLC By: /s/ Adam Koppel Title: Partner Bain Capital Life Sciences IV General Partner, LLC By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Adam Koppel Title: Partner Bain Capital Life Sciences Fund IV, L.P. By: Bain Capital Life Sciences IV General Partner, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Adam Koppel Title: Partner BCLS Fund IV Investments GP, LLC By: Bai…
Read attachment ↗